InvestorsHub Logo

Lemoncat

12/27/18 5:46 PM

#252785 RE: Rdunn88 #252782

It's not hard to envision such a fictional scenario:

"We opted to purchase Company I to acquire a lead anti-inflammatory candidate starting pivotal trials for $400 million. In addition we received potential IBD/Acne/HS candidates ranging from preclinical to mid-stage trials. Additionally, mid-stage p53 modulator was also acquired."

I think Pfizer, Roche, Novartis, or Merck shareholders would be very pleased with such an announcement.